KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Expenses: 2013-2025

Historic Accumulated Expenses for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $17.5 million.

  • Xenon Pharmaceuticals' Accumulated Expenses rose 95.75% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 95.75%. This contributed to the annual value of $12.1 million for FY2024, which is 36.68% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Accumulated Expenses stood at $17.5 million, which was up 14.80% from $15.2 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Accumulated Expenses high stood at $17.5 million for Q3 2025, and its period low was $1.3 million during Q1 2021.
  • Over the past 3 years, Xenon Pharmaceuticals' median Accumulated Expenses value was $8.8 million (recorded in 2023), while the average stood at $8.7 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Accumulated Expenses dropped by 1.97% in 2022 and then soared by 165.57% in 2025.
  • Xenon Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $5.9 million in 2021, then declined by 1.97% to $5.8 million in 2022, then surged by 51.54% to $8.8 million in 2023, then spiked by 36.68% to $12.1 million in 2024, then spiked by 95.75% to $17.5 million in 2025.
  • Its last three reported values are $17.5 million in Q3 2025, $15.2 million for Q2 2025, and $10.1 million during Q1 2025.